Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs

Virus Research

Volumn 103, Issue 1-2, 2004, Pages 205-211

  Hurt, Aeron C ^a   McKimm Breschkin, Jennifer L ^b   McDonald, Mandy ^b   Barr, Ian G ^a   Komadina, Naomi ^a   Hampson, Alan W ^a  

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^b CSIRO   (Australia)

Author keywords

Chemiluminescent; Fluorescent; Influenza; Neuraminidase inhibitors; Oseltamivir carboxylate; Reduced sensitivity; RWJ 270201; Zanamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMINO ACID; HEMAGGLUTININ; PERAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ANIMAL CELL; AUSTRALIA; CHEMOLUMINESCENCE; CONFERENCE PAPER; DOG; ENZYME ASSAY; FLUORESCENCE; IC 50; INFLUENZA VIRUS B; KIDNEY CELL; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS RESISTANCE; VIRUS STRAIN;

ACETAMIDES; ANTIVIRAL AGENTS; CHEMILUMINESCENT MEASUREMENTS; CYCLOPENTANES; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; GUANIDINES; HUMANS; INFANT; INFLUENZA B VIRUS; MICROBIAL SENSITIVITY TESTS; NEURAMINIDASE; OSELTAMIVIR; PYRANS; SIALIC ACIDS; ZANAMIVIR;

INFLUENZA B VIRUS;

EID: 2442570582     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2004.02.035     Document Type: Conference Paper

References (23)

1. Bantia, S., Ananth, S., Horn, L., Parker, C., Gulati, U., Chand, P., Babu, Y., Air, G., 2000. Generation and characterization of a mutant of influenza A virus selected with neuraminidase inhibitor RWJ-270201. The Thirteenth International Congress on Antiviral Research, Baltimore, MD, USA. Antiviral Res. 46(1) A60 (Abstract 82)
2. Bantia S., Parker C.D., Ananth S.L., Horn L.L., Andries K., Chand P., Kotian P.L., Dehghani A., El-Kattan Y., Lin T., Hutchison T.L., Montgomery J.A., Kellog D.L., Babu Y.S. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:2001;1162-1167
3. Barnett J.M., Cadman A., Burrell F.M., Madar S.H., Lewis A.P., Tisdale M., Bethell R. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology. 265:1999;286-295
4. Barnett J.M., Cadman A., Gor D., Dempsey M., Walters M., Candlin A., Tisdale M., Morley P.J., Owens I.J., Fenton R.J., Lewis A.P., Claas E.C., Rimmelzwaan G.F., De Groot R., Osterhaus A.D. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob. Agents Chemother. 44:2000;78-87
5. Belshe R.B., Smith M.H., Hall C.B., Betts R., Hay A.J. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62:1988;1508-1512
6. Buxton R.C., Edwards B., Juo R.R., Voyta J.C., Tisdale M., Bethell R.C. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal. Biochem. 280:2000;291-300
7. Carr J., Ives J., Kelly L., Lambkin R., Oxford J., Mendel D., Tai L., Roberts N. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 54:2002;79-88
8. Gubareva L.V., Matrosovich M.N., Brenner M.K., Bethell R.C., Webster R.G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1998;1257-1262
9. Gubareva L.V., Kaiser L., Hayden F.G. Influenza virus neuraminidase inhibitors. Lancet. 355:2000;827-835
10. Gubareva L.V., Webster R.G., Hayden F.G. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 53:2002;47-61
11. Hayden, F.G., 1996. Amantadine and rimantadine: clinical aspects. In: Richman, DD. (Ed.), Antiviral Drug Resistance. Wiley, New York, pp. 78-92.
12. Herlocher M.L., Carr J., Ives J., Elias S., Truscon R., Roberts N., Monto A.S. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 54:2002;99-111
13. Ives J., Carr J., Roberts N.A., Tai C.Y., Mendel D.B., Kelly L., Lambkin R., Oxford J. An oseltamivir treatment-selected influenza A:N2 virus with a R292K mutation in the neuraminidase gene has reduced infectivity in vivo. J. Clin. Virol. 18:2000;251-269
14. Ives J.A., Carr J.A., Mendel D.B., Tai C.Y., Lambkin R., Kelly L., Oxford J.S., Hayden F.G., Roberts N.A. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 55:2002;307-317
15. Jackson H.C., Roberts N., Wange Z.M., Belshe R. Management of influenza: use of new antivirals and resistance in perspective. Clin. Drug Invest. 20:2000;447-454
16. McKimm-Breschkin J.L., Sahasrabudhe A., Blick T.J., McDonald M., Colman P.M., Hart G.J., Bethell R.C., Varghese J.N. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J. Virol. 72:1998;2456-2462
17. McKimm-Breschkin J.L. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral. Res. 47:2000;1-17
18. McKimm-Breschkin J.L. Neuraminidase inhibitors for the treatment and prevention of influenza. Exp. Opin. Pharmacother. 3:2002;103-112
19. Potier M., Mameli L., Belisle M., Dallaire L., Melancon S.B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N- acetylneuraminate) substrate. Anal Biochem. 94:1979;287-296
20. Roberts N.A. Treatment of influenza with neuraminidase inhibitors: virological implications. Phil. Trans. R. Soc. Lond. B. Biol. Sci. 356:2001;1895-1897
21. Shaw M.W., Lamb R.A., Erickson B.W., Briedis D.J., Choppin P.W. Complete nucleotide sequence of the neuraminidase gene of influenza B virus. Proc. Natl. Acad. Sci. 79:1982;6817-6821
22. Wetherall N.T., Trivedi T., Zeller J., Hodges-Savola C., McKimm-Breschkin J.L., Zambon M., Hayden F.G. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the Neuraminidase Inhibitor Susceptibility Network. J. Clin. Microbiol. 41:2003;742-750
23. Zambon M., Hayden F.G. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 49:2001;47-56